Oxurion NV Cash Flow Conversion Efficiency
Oxurion NV cash flow conversion efficiency. Based on the latest financial reports, Oxurion NV (OXUR) has a cash flow conversion efficiency ratio of 0.097x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.16 Million ≈ $-1.36 Million USD) by net assets (€-11.99 Million ≈ $-14.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Oxurion NV (2006–2024)
Cash flow conversion efficiency of Oxurion NV from 2006 to 2024. This chart illustrates how Oxurion NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Oxurion NV for real-time trading data and today's change.
Oxurion NV Cash Flow Conversion Ratio Explained
Oxurion NV cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Oxurion NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oxurion NV ranked by their cash flow conversion efficiency. Also see OXUR market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fusion Antibodies PLC
LSE:FAB
|
-0.792x |
|
Tanfield Group PLC
LSE:TAN
|
0.000x |
|
CRISM Therapeutics Corporation
LSE:CRTX
|
-0.574x |
|
GOLDEN SHIELD RESOURCES
F:4LE0
|
N/A |
|
SEEEN PLC
LSE:SEEN
|
1.594x |
|
Sentia Asa
OL:SNTIA
|
-0.272x |
|
Abacus Global Management, Inc.
NASDAQ:ABX
|
-0.075x |
|
KINGMAN MINERALS LTD.
F:47A
|
-0.113x |
Annual Cash Flow Conversion Efficiency for Oxurion NV (2006–2024)
The table below shows the annual cash flow conversion efficiency of Oxurion NV from 2006 to 2024. Review free cash flow generation of Oxurion NV to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-11.06 Million ≈ $-12.93 Million |
€-2.07 Million ≈ $-2.42 Million |
0.187x | -74.75% |
| 2023-12-31 | €-13.19 Million ≈ $-15.42 Million |
€-9.77 Million ≈ $-11.42 Million |
0.741x | -83.04% |
| 2022-12-31 | €-4.58 Million ≈ $-5.36 Million |
€-20.02 Million ≈ $-23.40 Million |
4.367x | -82.18% |
| 2021-12-31 | €-1.11 Million ≈ $-1.30 Million |
€-27.16 Million ≈ $-31.75 Million |
24.508x | +2365.49% |
| 2020-12-31 | €25.05 Million ≈ $29.28 Million |
€-27.10 Million ≈ $-31.68 Million |
-1.082x | -85.42% |
| 2019-12-31 | €53.31 Million ≈ $62.32 Million |
€-31.10 Million ≈ $-36.36 Million |
-0.583x | -97.46% |
| 2018-12-31 | €105.31 Million ≈ $123.12 Million |
€-31.12 Million ≈ $-36.38 Million |
-0.295x | -249.85% |
| 2017-12-31 | €133.36 Million ≈ $155.91 Million |
€26.30 Million ≈ $30.74 Million |
0.197x | +206.66% |
| 2016-12-31 | €109.86 Million ≈ $128.44 Million |
€-20.31 Million ≈ $-23.74 Million |
-0.185x | -13.08% |
| 2015-12-31 | €170.01 Million ≈ $198.77 Million |
€-27.79 Million ≈ $-32.49 Million |
-0.163x | +27.00% |
| 2014-12-31 | €208.01 Million ≈ $243.19 Million |
€-46.58 Million ≈ $-54.46 Million |
-0.224x | -325.38% |
| 2013-12-31 | €258.77 Million ≈ $302.53 Million |
€25.71 Million ≈ $30.06 Million |
0.099x | -18.50% |
| 2012-12-31 | €227.97 Million ≈ $266.52 Million |
€27.79 Million ≈ $32.49 Million |
0.122x | +173.54% |
| 2011-12-31 | €118.03 Million ≈ $137.99 Million |
€-19.56 Million ≈ $-22.87 Million |
-0.166x | -36.00% |
| 2010-12-31 | €138.19 Million ≈ $161.56 Million |
€-16.84 Million ≈ $-19.69 Million |
-0.122x | +5.59% |
| 2009-12-31 | €93.72 Million ≈ $109.57 Million |
€-12.10 Million ≈ $-14.14 Million |
-0.129x | -167.36% |
| 2008-12-31 | €62.39 Million ≈ $72.94 Million |
€11.96 Million ≈ $13.98 Million |
0.192x | +162.73% |
| 2007-12-31 | €48.44 Million ≈ $56.63 Million |
€-14.80 Million ≈ $-17.30 Million |
-0.306x | -28.03% |
| 2006-12-31 | €35.28 Million ≈ $41.24 Million |
€-8.42 Million ≈ $-9.84 Million |
-0.239x | -- |
About Oxurion NV
Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness in Belgium. The company is developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991… Read more